Drug Trial Radar · NCT06112340
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Last checked: Nov 19, 2026Latest source record: Feb 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Oct 11, 2023
Primary completion
Jun 2026
Study completion Jun 2026
Sponsor
- Lead sponsor
- Sling Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24. These subjects include VGN-TED-301 Week 24 proptosis non-responders or subjects who relapse during the Follow-Up Period of VGN-TED-301.
Conditions
- Thyroid Eye Disease
- Graves Orbitopathy
- Endocrine System Diseases
- Eye Diseases
- Thyroid Associated Ophthalmopathy
- Graves Ophthalmopathy
- Thyroid Diseases
- Orbital Diseases
- Proptosis
- IGF1R
- Exophthalmos
- Hashimoto
Interventions
linsitinibDrug
Study medication taken twice daily by mouth
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects who are Proptosis Responders at Week 24Time frame: 24 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Bascom Palmer Eye Institute
Miami, Florida · Recruiting
West Virginia University Eye Institute
Morgantown, West Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.